[Mechanism of the anti-arrhythmia action of potassium and magnesium nicotinates].
It has been shown in rat experimental aconitinic arrhythmia and in dog postinfarction arrhythmia that combined potassium and magnesium nicotinates show a pronounced anti-arrhythmic effect. The studies on the drug distribution in the tissues indicate that the content of potassium, magnesium and total coenzymatic forms of nicotinic acid rises in the myocardium by the 12th hour from the commencement of the drug administration. Intracellular and exocellular content of potassium and sodium has been shown to return to normal.
D000818:Animals; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D004285:Dogs; D004338:Drug Combinations; D004353:Drug Evaluation, Preclinical; D007700:Kinetics; D008274:Magnesium / Q000378:metabolism / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy; D009539:Nicotinic Acids / Q000378:metabolism / Q000627:therapeutic use*; D011188:Potassium / Q000378:metabolism / Q000627:therapeutic use*; D051381:Rats; D014018:Tissue Distribution
D000889:Anti-Arrhythmia Agents; D004338:Drug Combinations; D009539:Nicotinic Acids; D008274:Magnesium; D011188:Potassium
K mekhanizmu antiaritmicheskogo dĭstviia nikotinatov kaliia i magniia.